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Editorial Comment
Cardiogenic Shock Complicating
Myocardial Infarction*
THOMAS KILLIP, MD, FACC
New York, New York
Despite more than 25 years of observation and treatment in
the cardiac care unit, cardiogenic shock complicating myo-
cardial infarction is the leading cause of death after hospital
admission . Mortality remains high despite the widespread
use of pressor agents, newer inotropic drugs and mechanical
circulatory support (1) .
The incidence of cardiogenic shock complicating myocar-
dial infarction appears to have declined in recent years . Of
2, 33 patients meeting MILIS study group criteria for pre-
sumed myocardial infarction, only 131 (4 .5%) were in func-
tional class IV (cardiogenic shock) on entry into the study
(Moller JLS, personal communication) . Trends toward ear-
lier hospitalization of the symptomatic patient and, more
recently, administration of thrombolytic agents may be
contributing to the apparent decline . Additionally, the clini-
cian avidly seeks treatable causes of circulatory collapse,
including hypovolemia, acute mitral valve dysfunction, ac-
quired ventricular septal defect and, occasionally, pericar-
dial hemorrhagic tamponade or external rupture with
pseudoaneurysm .
Pathologic studies (2,3) have established that cardiogenic
shock develops when a major portion of the left ventricle-
usually ?40%-is dysfunctional because of ischemia or
infarction . The loss of left ventricular mass may reflect
extensive recent infarction, or some combination of one or
more old infarct scars combined with fresh necrosis that
exceeds a critical threshold of destruction . It is the total
amount of left ventricular damage that counts, not when it
occurred (2). The occasional survivor from massive infarc-
tion usually has severe functional limitations and a poor
prognosis . A recent echocardiographic study (4) suggests
that altered function of the noninfarcted myocardium may
also contribute to the shock syndrome .
Current treatment remains unsatisfactory .
Because the
amount of dysfunctional myocardium appears to be the
major factor contributing to the development of cardiogenic
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shock complicating myocardial infarction, treatment aimed
at relieving coronary artery occlusion and restoring nutri-
tional flow to the ischemic myocardium appears reasonable .
Certainly, the evidence that treatment with vasodilators,
pressors or inotropic agents improves survival has not been
convincing . Mechanical support of the circulation has also
had limited success (5) . Emergency coronary bypass surgery
has had its proponents, but reports (6) of success have been
viewed with skepticism because of possibilities of selection
bias . Thrombolytic agents may be effective, but definitive
studies are lacking . More recently, reports (7) on the value of
emergency angioplasty in cardiogenic shock have appeared .
Although suggestive, such studies have lacked controls or
have comprised retrospective comparisons of treated and
untreated patients .
The present study . Treatment of cardiogenic shock would
clearly be enhanced if patients at risk could be identified
early in the course of illness . In this issue of the Journal,
Hands and coworkers (8) from the MILLS study group report
data on the in-hospital development of cardiogenic shock
from >2,800 patients with myocardial infarction studied
prospectively . Shock developed after hospitalization in 7 .1%
with a mortality rate of 65%. In more than half of the
patients, the complication developed >24 h after admission ;
average time to development was 3 .4 days after arrival . Not
surprisingly, evidence of poor left ventricular function had
both predictive and prognostic value .
Why is shock delayed, often for several days after the
initial insult? The authors (8) suggest that the major culprit is
infarct extension, which occurred in almost two-thirds of the
patients with shock before or at the onset of shock . Their
hypothesis is reasonable because pathologic studies ( ) have
shown that many patients succumbing to shock have multi-
ple recent infarcts of different apparent histologic age . In-
farct expansion with consequent hemodynamic deterioration
may also play a role (10) . Persistent hypoxia secondary to
left ventricular failure and pulmonary congestion may also
contribute to collapse of hemodynamic compensation in
states of persistent low cardiac output .
Statistical analysis of the data (8) revealed that indepen-
dent predictors for the in-hospital development of cardio-
genic shock included age, initial left ventricular ejection
fraction <0.35, high MB creatine kinase level, history of
diabetes mellitus and previous myocardial infarction . The
presence of three or more of these factors predicted a risk of
about 18% for the subsequent development of cardiogenic
shock; with five risk factors, the probability was slightly
>50% .
Hands et al . (8) suggest that the delay from onset of acute
infarction to development of cardiogenic shock as observed
in this study may permit early recognition of the patient at
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risk and, hence, the application of aggressive preventative
therapy . This is an interesting proposal although even the
presence of five risk factors predicted shock only half the
time . The hypothesis of Hands et al. is testable . Cardiogenic
shock in myocardial infarction implies massive myocardial
damage. Myocardial infarction is most often precipitated by
coronary thrombosis . Restoration of nutrient flow may limit
the damage . Angioplasty may restore coronary artery pa-
tency in the acutely ill patient . It all makes sense . If
angioplasty is an effective treatment for cardiogenic shock, it
will have to be demonstrated in a well designed, randomized
trial in suitable cases. Perhaps the study of Hands et al . (8)
offers some new, exciting possibilities for reducing mortality
in cardiogenic shock by identifying patients at risk after the
initial insult and permitting a definitive trial of aggressive
therapy .
References
I . Billhardt RA, Rosenbush SW . Cardiogenic and hypovolemic shock . Med
Clin North Am 1 86 ;70  853-76 .
2 . Alonso DR, Scheidt S, Post M, Killip T . Pathophysiology of cardiogenic
JACC Vol . 14, No. I
July 1 8  47-8
shock   quantification of myocardial necrosis, clinical pathologic and
electrocardiographic correlation . Circulation 1 73 ;48  588- 6 .
3 . Page DL, Caulfield JB, Kastor JA, et al . Myocardial changes associated
with cardiogenic shock . N Engl J Med 1 71 ;285
 133-7
.
4 . Widimsky P, Gregor P, Cervenka V, et al . Severe diffuse hypokinesis of
the remove myocardium-the main cause of cardiogenic shock? An
echocardiographic study of 75 patients with extremely large myocardial
infarctions . Cor Vasa 1 88 ;30 27-34
.
5 . Moulopoulos S, Stamatelopoulos S, Petrou P . Intraaortic balloon assis-
tance in intractable cardiogenic shock . Eur Heart J 1 86 ;7  3 6-403 .
6 . Guyton RA, Arcidi JM Jr, Langford DA, Morris DC, Liberman HA,
Hatcher CR Jr. Emergency coronary bypass for cardiogenic shock .
Circulation 1 87  76(suppl V) V-22-7 .
7 . Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O'Neill WW
. Percuta-
neous transluminal coronary angioplasty improves survival in acute
myocardial infarction complicated by cardiogenic shock . Circulation
1 88  87  1345-51
.
8 . Hands ME, Rutherford JD, Muller JE, et al . The in-hospital development
of cardiogenic shock after myocardial infarction   incidence, predictors of
occurrence, outcome and prognostic factors . J Am Coll Cardiol 1 8  ;
14  40-6 .
  . Gutovitz AL, Sobel BE, Roberts R . Progressive nature of myocardial
injury in selected patients with cardiogenic shock . Am J Cardiol 1 78 ;
41  46 -75 .
10 . Weisman HF, Healy B . Myocardial infarct expansion, infarct extension
and reinfarction
  pathophysiologic concepts . Prog Cardiovasc Dis 1 87 ;
30  73-110 .
